"We are investigating how the marketing approval and import license were granted to Generex Biotechnology and then later transferred to Shreya Life Sciences," DCGI's Surinder Singh told Mint in an April 15, 2009 story.
Surinder, who was not at DCGI at the time Oral-lyn was approved in 2007, further told Mint, "What was the basis on which the approval was given to the company? Until the investigation is complete and a decision is taken, the product cannot be sold."
Ram Shelat, director of domestic business at Shreya, told Mint, "Based on DCGI's letter, we have stopped sales and dispatches of the product. We have not placed any further order to Generex for import."
By April 2009, less than four months after Generex and Shreya began selling Oral Recosulin (Oral-lyn) in India, the diabetes treatment was yanked from the market. Yet it seems that Generex didn't disclose to shareholders or investors that its Indian business had unraveled.
Investors question GenerexSearching SEC filings for the 8-K form that Generex should have filed disclosing the Indian government's action against Oral-lyn on March 26, 2009 doesn't turn anything up. Subsequent quarterly and annual reports filed by Generex with the SEC do not contain any disclosure about the halt to Oral-lyn sales in India. And if the company issued any press releases discussing the India news, they're not posted to its Web site. On an Oct. 19, 2009 conference call, a private investor asked Generex CEO Gluskin for an update on Oral-lyn sales in India. "Are you seeing more doctors prescribing the medication there now as opposed to, let's just say, three months ago?" he asked, according to a transcript of the conference call. Gluskin replied, "Our progress in India is monitored by our partner, Shreya Biotech. And as you know, a condition of our approval was Phase IV, so that Phase IV trial we just marked as surveillance is continuing. We do not have specific numbers on sales yet, but we certainly are working towards getting an update and we certainly would be continuously monitoring that situation." The investor then asks a follow-up question about Oral-lyn in India, which prompted Generex Vice President for Finance Stephen Fellows to respond:
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV